Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
Conditions
Brief summary
Overall response rate (ORR) as assessed by PET-CT (FL) or CT (MZL) using "The Lugano Classification".
Detailed description
Complete response rate (CRR) as assessed by PET-CT (FL) or CT (MZL) using "The Lugano Classification"., Duration of Response (DOR) if Best Overall Response (BOR) is CR, as assessed by PET-CT and/or CT using "The Lugano Classification"., Duration of Response (DOR) as assessed by PET-CT and/or CT using "The Lugano Classification"., Progression Free Survival (PFS) as assessed by PET-CT and/or CT using "The Lugano Classification"., Overall Survival (OS), Safety, Pharmacokinetics (PK), Health-related quality of life (HRQoL)
Interventions
Sponsors
Celgene Corp.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate (ORR) as assessed by PET-CT (FL) or CT (MZL) using "The Lugano Classification". | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete response rate (CRR) as assessed by PET-CT (FL) or CT (MZL) using "The Lugano Classification"., Duration of Response (DOR) if Best Overall Response (BOR) is CR, as assessed by PET-CT and/or CT using "The Lugano Classification"., Duration of Response (DOR) as assessed by PET-CT and/or CT using "The Lugano Classification"., Progression Free Survival (PFS) as assessed by PET-CT and/or CT using "The Lugano Classification"., Overall Survival (OS), Safety, Pharmacokinetics (PK), Health-related quality of life (HRQoL) | — |
Countries
Austria, France, Germany, Italy, Spain, Sweden
Outcome results
None listed